Lactobacillus reuteri strain combination in helicobacter pylori infection: A randomized, double-blind, placebo-controlled study

Ruggiero Francavilla, Lorenzo Polimeno, Antonella Demichina, Giovanni Maurogiovanni, Beatrice Principi, Giuseppe Scaccianoce, Enzo Ierardi, Francesco Russo, Giuseppe Riezzo, Alfredo Di Leo, Luciano Cavallo, Antonio Francavilla, James Versalovic

Research output: Contribution to journalArticlepeer-review

58 Scopus citations

Abstract

Goals: The goals of this study were to investigate the role of a new probiotic preparation (Lactobacillus reuteri DSM 17938 and L. reuteri ATCC PTA 6475) in Helicobacter pylori infection. Background: Specific probiotic strains play a role in H. pylori infection for their ability to decrease bacterial load and gastritis, prevent antibiotic-associated side effects, and increase the eradication rate. Study: This is a prospective, double-blind, randomized, placebo-controlled study in a tertiary care setting. A total of 100 H. pylori-positive naive patients received either L. reuteri combination (2×10 Colony Forming Units) or placebo during a 3-phase study (pre-eradication, eradication, and follow-up). All underwent C urea breath test (C-UBT), blood assessments of gastrin-17 (G17), endoscopy, and the Gastrointestinal Symptom Rating Scale. Eradication was confirmed by C-UBT 8 weeks after the completion of therapy. Results: Fifty patients were allocated in each group. During pre-eradication period, C-UBT δ decreased by 13% in L. reuteri combination as compared with a 4% increase in placebo (-13.2±34% vs. 4.3±27%; P<0.03). During eradication, GSRS increased significantly in placebo as compared with L. reuteri combination (6.8±2.9 vs. 4±3.1; P<0.01). Significantly less patients in L. reuteri combination as compared with placebo-reported side effects (40.9% vs. 62.8%; P<0.04). An abnormal G17 value was found in patients receiving placebo as compared with L. reuteri combination (28% vs. 12%; P<0.02). Eradication rate was 75% in L. reuteri combination and 65.9% in placebo (P=NS). L. reuteri combination increased eradication rate by 9.1% (odds ratio: 1.5). Conclusions: L. reuteri combination alone is able to exert an inhibitory effect on H. pylori growth, and when administered with eradication therapy, it determines a significant reduction in antibiotic-associated side effects. Moreover, L. reuteri combination was able to decrease serum G17 levels and to (not significantly) increase the H. pylori-eradication rate.

Original languageEnglish (US)
Pages (from-to)407-413
Number of pages7
JournalJournal of Clinical Gastroenterology
Volume48
Issue number5
DOIs
StatePublished - Jan 1 2014

Keywords

  • antibiotic-associated side effects
  • bacterial load
  • eradication therapy
  • Helicobacter pylori
  • probiotics

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Lactobacillus reuteri strain combination in helicobacter pylori infection: A randomized, double-blind, placebo-controlled study'. Together they form a unique fingerprint.

Cite this